REVB
Revelation BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The earnings follow-up modestly improves the monitoring setup only if investors accept that the May 7 8-K financial-results update and ongoing AKI study preparation can bridge to a credible 2026 trial-start milestone [#8-K-2026-05-07] [#10-K-2026-02-26].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
AKI study-start timing remains uncertain; preparation for a study is not the same as trial initiation or enrollment.
Momentum
86
Value
57
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.85 · Bull $1.40 · Bear $0.45
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $19.25
Why
Momentum86 · Δ7d -
Value57 · Δ7d -0.2
Sentiment20 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
86
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.1
Sentiment
20
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 86.3 / Value 57.1 / Sentiment 20.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$4.61M
Beta
-0.11
Shares Out
3.91M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.08
Rev YoY
-
EPS YoY
-89.3%
Gross Margin
-
Op Margin
-
Net Debt
-$9.95M
Current Ratio
10.02
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology